Literature DB >> 8398361

Erythropoietin for anaemia in cancer patients.

R Abels1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8398361     DOI： 10.1016/s0959-8049(05)80281-3

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  23 in total

1.  Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients.

Authors:  Vicente Alberola Candel; Alfredo Carrato Mena; Eduardo Díaz-Rubio García; Pere Gascón Vilaplana; Manuel González Barón; Miguel Martín Jiménez; Emilio Alba Conejo; Javier Cassinello Espinosa; Ramon Colomer; Juan Jesús Cruz Hernández; Agustí Barnadas i Molins; Carlos Camps Herrero; Ana Ma Casas Fernández de Tejerina; Joan Carulla Torrent; Manuel Constenla Figueiras; Joaquin Gavilá Gregori; Ma Dolores Isla Casado; Bartomeu Massuti Sureda; Mariano Provencio Pulla; César Augusto Rodríguez Sánchez; Jaime Sanz Ortiz
Journal:  Clin Transl Oncol       Date:  2009-11       Impact factor: 3.405

2.  Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer.

Authors:  Philippe Fagnoni; Samuel Limat; Loïc Chaigneau; Emmanuel Guardiola; Stéphanie Briaud; Bernard Schmitt; Yacine Merrouche; Xavier Pivot; Marie-Christine Woronoff-Lemsi
Journal:  Support Care Cancer       Date:  2006-06-27       Impact factor: 3.603

Review 3.  Erythropoietin or darbepoetin for patients with cancer.

Authors:  Thomy Tonia; Annette Mettler; Nadège Robert; Guido Schwarzer; Jerome Seidenfeld; Olaf Weingart; Chris Hyde; Andreas Engert; Julia Bohlius
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

Review 4.  Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis.

Authors:  Sheng Gao; Jing-Jing Ma; Cheng Lu
Journal:  Tumour Biol       Date:  2014-01

Review 5.  Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia.

Authors:  P Y Cremieux; S N Finkelstein; E R Berndt; J Crawford; M B Slavin
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

Review 6.  Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies.

Authors:  David H Henry
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 7.  Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis.

Authors:  Marcello Tonelli; Brenda Hemmelgarn; Tony Reiman; Braden Manns; M Neil Reaume; Anita Lloyd; Natasha Wiebe; Scott Klarenbach
Journal:  CMAJ       Date:  2009-04-30       Impact factor: 8.262

Review 8.  A risk-benefit assessment of epoetin in the management of anaemia associated with cancer.

Authors:  Y Beguin
Journal:  Drug Saf       Date:  1998-10       Impact factor: 5.606

9.  Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline.

Authors:  J Vansteenkiste; D Tomita; G Rossi; R Pirker
Journal:  Support Care Cancer       Date:  2004-01-23       Impact factor: 3.603

10.  Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.

Authors:  J Glaspy; J Crawford; J Vansteenkiste; D Henry; S Rao; P Bowers; J A Berlin; D Tomita; K Bridges; H Ludwig
Journal:  Br J Cancer       Date:  2010-01-05       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.